B
Bo Feng
Researcher at Shanghai Jiao Tong University
Publications - 79
Citations - 2121
Bo Feng is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 20, co-authored 70 publications receiving 1559 citations. Previous affiliations of Bo Feng include Ruijin Hospital.
Papers
More filters
Journal ArticleDOI
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST
Xiao Yang,Sen Zhang,Changyu He,Pei Xue,Luyang Zhang,Zirui He,Lu Zang,Bo Feng,Jing Sun,Minhua Zheng +9 more
TL;DR: Functionally, knockdown of METTL14 drastically enhanced proliferative and invasive ability of CRC cells in vitro and promoted tumorigenicity and metastasis in vivo and extended the understanding of the importance of RNA epigenetics in cancer biology.
Journal ArticleDOI
Distinct urinary metabolic profile of human colorectal cancer.
Yu Cheng,Guoxiang Xie,Tianlu Chen,Yunping Qiu,Xia Zou,Minhua Zheng,Binbin Tan,Bo Feng,Tao-Tao Dong,Pingang He,Linjing Zhao,Aihua Zhao,Lisa X. Xu,Yan Zhang,Wei Jia,Wei Jia +15 more
TL;DR: These findings confirm distinct urinary metabolic footprints of CRC patients characterized by altered levels of metabolites derived from gut microbial-host co-metabolism and provide a novel and promising molecular diagnostic approach for the early detection of CRC.
Journal ArticleDOI
Metabonomics identifies serum metabolite markers of colorectal cancer.
Binbin Tan,Yunping Qiu,Xia Zou,Tianlu Chen,Guoxiang Xie,Yu Cheng,Tao-Tao Dong,Linjing Zhao,Bo Feng,Xiaofang Hu,Lisa X. Xu,Aihua Zhao,Menghui Zhang,Guoxiang Cai,Sanjun Cai,Zhanxiang Zhou,Minhua Zheng,Yan Zhang,Wei Jia +18 more
TL;DR: A follow-up replication study aiming to identify a distinct serum metabolic signature of CRC with diagnostic potential demonstrated that a panel of serum metabolite markers is of great potential as a noninvasive diagnostic method for the detection of CRC.
Journal ArticleDOI
Salinomycin Selectively Targets ‘CD133+’ Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines
TL;DR: The ability of salinomycin to selectively target “CD133+” cell subpopulations and decrease the malignant traits in colorectal cancer lines is demonstrated.
Journal ArticleDOI
Laparoscopic complete mesocolic excision (CME) with medial access for right-hemi colon cancer: feasibility and technical strategies.
Bo Feng,Jing Sun,Tian-Long Ling,Ai-Guo Lu,Ming-Liang Wang,Xue-Yu Chen,Junjun Ma,Jianwen Li,Lu Zang,Ding-Pei Han,Minhua Zheng +10 more
TL;DR: CME is a novel concept for colon cancer surgery and might be a standard for the procedure, but randomized trials are needed to evaluate its long-term outcomes.